Shares of Integer Holdings Co. (NYSE:ITGR – Get Free Report) have received an average recommendation of “Moderate Buy” from the nine research firms that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $148.56.
A number of equities analysts have recently commented on the company. Benchmark boosted their target price on Integer from $140.00 to $150.00 and gave the company a “buy” rating in a research report on Friday, February 21st. KeyCorp boosted their price objective on shares of Integer from $144.00 to $154.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. Oppenheimer cut shares of Integer from an “outperform” rating to a “market perform” rating in a research note on Friday, February 21st. Finally, Raymond James began coverage on shares of Integer in a report on Friday, March 28th. They set an “outperform” rating and a $145.00 price target on the stock.
View Our Latest Report on Integer
Institutional Trading of Integer
Integer Price Performance
ITGR stock opened at $113.84 on Friday. The company has a fifty day simple moving average of $124.34 and a two-hundred day simple moving average of $131.00. Integer has a 52 week low of $104.93 and a 52 week high of $146.36. The company has a quick ratio of 2.09, a current ratio of 2.95 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $3.83 billion, a P/E ratio of 33.88, a price-to-earnings-growth ratio of 1.72 and a beta of 1.09.
Integer (NYSE:ITGR – Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 EPS for the quarter, missing analysts’ consensus estimates of $1.46 by ($0.03). Integer had a net margin of 6.92% and a return on equity of 11.65%. The business had revenue of $449.50 million during the quarter, compared to the consensus estimate of $446.28 million. Analysts anticipate that Integer will post 6.01 earnings per share for the current fiscal year.
Integer Company Profile
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.
See Also
- Five stocks we like better than Integer
- Options Trading – Understanding Strike Price
- Joby Aviation: Operational Momentum vs. Market Sentiment
- Overbought Stocks Explained: Should You Trade Them?
- Broadcom’s Big Outperformance Shows Strength Amid Tariff Decline
- What does consumer price index measure?
- Carvana: Can Turnaround Strength Outdrive Market Headwinds?
Receive News & Ratings for Integer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integer and related companies with MarketBeat.com's FREE daily email newsletter.